Financing will enable Miach Orthopaedics continued growth of their commercial organization in the U.S., as well as support clinical initiatives like the Bridge Registry to provide important data on real-world patient outcomes.
Miach Orthopedics initiated BEAR III to continue to build upon the extensive base of evidence for the BEAR Implant, which recently received De Novo approval from the U.S. Food and Drug Administration.
This May, OrthoInfo.org, the authoritative and trusted source on bone and joint health, is joining organizations across the country to raise awareness about prevention strategies that can help reduce one's risk of developing osteoporosis.